immuno-oncology

News

Roche bags EU okay for subcutaneous Tecentriq

Roche has been given EU approval for a new formulation of its cancer immunotherapy Tecentriq that aims to make dosing easier for patients, nurses, and physicians.

News

Rumour mill says MSD is hunting Harpoon Therapeutics

MSD’s 2023 run of pipeline-building deals looks like it could continue into this year, with reports already emerging that the company is in talks to buy Harpoon Therapeuti

News

AbbVie is big pharma’s first mover in ‘in situ’ cell therapy

AbbVie has signed a wide-ranging collaboration with Umoja Biopharma in the area of ‘in situ’ or in vivo cell therapy, an emerging strategy that does away with the need to

News

Astellas strikes $1.7bn SIRP drug deal with Elpiscience

Astellas has struck a deal with fellow Japanese pharma company Elpiscience to develop up to four cancer immunotherapies that work by revving up the activity of macrophages

News

AZ makes another cell therapy play with $1.2bn Gracell buy

AstraZeneca has lined up a $1.2 billion takeover deal for Chinese biotech Gracell Biotechnologies, bolting a series of cell therapies for cancer and autoimmune diseases on

News

FDA says no to Checkpoint’s skin cancer drug cosibelimab

Checkpoint Therapeutics’ late entry into the PD-1/PD-L1 inhibitor category, cosibelimab, just got knocked back even further after it was turned down by the FDA as a treatm

Roche bags EU okay for subcutaneous Tecentriq

Rumour mill says MSD is hunting Harpoon Therapeutics

AbbVie is big pharma’s first mover in ‘in situ’ cell therapy

Astellas strikes $1.7bn SIRP drug deal with Elpiscience

AZ makes another cell therapy play with $1.2bn Gracell buy

FDA says no to Checkpoint’s skin cancer drug cosibelimab

On AI and computational support of biochemistry, with Alan R...

The AI imperative: Establishing the standard for modern clin...

immuno-oncology

Editor's Picks